The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer
BackgroundWe aimed to report our clinical experience with the use of 225Ac-PSMA-617 in the treatment of mCRPC patients.MethodsA retrospective analysis was conducted on 29 metastatic castration-resistant prostate cancer (mCRPC) patients treated with 225Ac-PSMA-617. Patients underwent treatment at 8-w...
Zapisane w:
| Główni autorzy: | , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Frontiers Media S.A.
2025-02-01
|
| Seria: | Frontiers in Oncology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1516860/full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|